About CSL112 CSL112 is a novel formulation of apolipoprotein A-I
(apoA-I), the primary functional component of high-density lipoprotein (HDL).
The paradox of high apolipoprotein A-I
levels independently predicting incident type-2 diabetes among Turks.
Additionally, TB increased apolipoprotein A-I
concentrations and decreased apolipoprotein B concentrations.
By sequencing 3 genes known to be key for the metabolism of HDL cholesterol [ATP-binding cassette, sub-family A (ABC1), member 1 (ABCA1), apolipoprotein A-I
(APOA1), and lecithin-cholesterol acyltransferase (LCAT)] in DHS individuals with extremely low and high HDL concentrations, Hobbs and Victor found that the number of mutations was 5 times higher in the low-HDL group than in the high-HDL group.
Secondary measures included VLDL cholesterol, apolipoprotein A-I
, and apolipoprotein B.
We therefore investigated the effect of testosterone on the gene expression of apolipoprotein A-I
(apoA-I), hepatic lipase (HL), scavenger receptor B1 (SR-BI), and the ATP binding cassette transporter A1 (ABCA1), all of which are important regulators of HDL metabolism.
Lab tests included total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), non-HDL-cholesterol (non HDL-C), fasting glycemia, serum creatinine, Lp(a), apolipoprotein A-I
(ApoA-I) and apolipoprotein B (ApoB) and fibrinogen.
The Phase 2 ASSERT clinical trial's lead compound RVX-208 is an orally active small molecule that raises Apolipoprotein A-I
(ApoA-I) production, the key protein in high-density lipoprotein (HDL) known as the 'good cholesterol'.
By determining the structure of HDL, the researchers were able to conclude that the majority of physiological interactions occurring with HDL-including its twisting movements-occur at the particle surface, which is dominated by the cardioprotective protein apolipoprotein A-I
Plasma apolipoprotein A-I
and B concentrations in growth-retarded fetuses.
Researchers tested an experimental drug formed by merging a body compound, called apolipoprotein A-I
, and a soybean compound.
Steady-state levels of acyl CoA oxidase (ACO); 3-hydroxy, 3-methylglutaryl CoA reductase (HMG-R); and apolipoprotein A-I
(Apo A-I) mRNA were examined after 24-hour incubation in the absence (control) or presence of 100 [micro]m each of linoleic acid (LA), cis-9, traps-11 CLA or traps-10, cis-12 CLA.